150.69MMarket Cap
24.01P/E TTM
Protalix Biotherapeutics Inc
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated: 2025-09-19 Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score Analysis
Current score
Previous score
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Financial Health
Currency: USD Updated: 2025-09-19The company's current financial score is 7.46, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.66M, representing a year-over-year increase of 16.21%, while its net profit experienced a year-over-year increase of 107.44%.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
No Data
Key Metrics
Cash flow from operating activities
Income after tax
No Data
Key Metrics
Cash flow from operating activities
Total revenue
No Data
Key Metrics
Free cash flow
No Data
Company Valuation
Currency: USD Updated: 2025-09-19The company’s current valuation score is 6.83, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 20.94, which is -28.84% below the recent high of 14.90 and 121.63% above the recent low of -4.53.
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 30/175
No Data
Earnings Forecast
Currency: USD Updated: 2025-09-19The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Protalix Biotherapeutics Inc is 14.00, with a high of 15.00 and a low of 13.00.
Support & Resistance
No Data
Strong Buy
Buy
Hold
Sell
Strong Sell
Protalix Biotherapeutics Inc
PLX
1
Vertex Pharmaceuticals Inc
VRTX
32
Alnylam Pharmaceuticals Inc
ALNY
32
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-09-19The company’s current price momentum score is 8.85, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 2.05 and the support level at 1.60, making it suitable for range-bound swing trading.
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2025-09-19Institutional Shareholding
No Data
Shareholder Activity
Northern Trust Global Investments Limited
Connor, Clark & Lunn Investment Management Ltd.
State Street Global Advisors (US)
Risk Assessment
Currency: USD Updated: 2025-09-19The company’s current risk assessment score is 3.20, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is -0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Beta vs S&P 500 index
-0.19
240-Day Maximum Drawdown
+56.03%
240-Day Volatility
+66.95%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Protalix Biotherapeutics Inc
PLX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Supernus Pharmaceuticals Inc
SUPN
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
